Vir Biotechnology Q1 net loss narrows to $65.3M; CFO stepping down; pipeline catalysts ahead

Vir Biotechnology, Inc.

2024-Q1 EPS reported -$0.48 revenue$56,376,000

Net loss of $65.3M ($0.48 loss per share) vs $140.9M ($1.06) in Q1 2023; revenue $56.4M down 10.5% YoY.
Cash, equivalents & investments $1.51B, down $118M in Q1; FY2024 R&D+SG&A guidance reaffirmed $650-680M.
CFO Sung Lee stepping down effective May 3; successor search initiated.
SOLSTICE hepatitis delta late-breaker abstract accepted at EASL June; 24-week data expected Q4 2024.
MARCH hepatitis B data and HIV VIR-1388 immunogenicity data expected H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Vir Biotechnology, Inc. reported first quarter ended March 31, 2024 results: revenue $56.4 million.

Period: first quarter ended March 31, 2024
Revenue: $56.4 million
Result: reported results

Exact text from the filing

cash equivalents and investments declined by approximately $118 million during the first quarter of 2024. Revenues: Total revenues for the quarter ended March 31, 2024, were $56.4 million compared to $63.0 million for the same period in 2023. Revenues were comprised of the following components: Three Months Ended March 31, 2024 2023 % Change (in millions)

View on SEC.gov

243 earnings releases filed in the last 30 days. Browse all earnings releases →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-020009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.